A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2016
At a glance
- Drugs SHR 0302 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 18 Apr 2016 Planned initiation date changed from 1 Feb 2016 to 1 May 2016.
- 15 Feb 2016 New trial record